Media stories about Organovo (NASDAQ:ONVO) have trended somewhat positive on Monday, Accern reports. The research firm identifies negative and positive press coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Organovo earned a news sentiment score of 0.11 on Accern’s scale. Accern also assigned press coverage about the medical research company an impact score of 45.2860510239233 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
These are some of the news stories that may have impacted Accern Sentiment’s analysis:
- Where Will Organovo Holdings, Inc. Be in 5 Years? (fool.com)
- Organovo Holdings, Inc. (ONVO) – Technical in Focus – Wall Street Morning (wallstreetmorning.com)
- Organovo Holdings, Inc. (NASDAQ:ONVO) – Hot Stock to Track – Nasdaq Journal (press release) (nasdaqjournal.com)
- Intraday Trade Secrets: Organovo Holdings Inc (NASDAQ: ONVO) – Alpha Beta Stock (alphabetastock.com)
- Organovo Holdings, Inc. (NASDAQ:ONVO) – Hot Stock of the Day – Nasdaq Journal (press release) (nasdaqjournal.com)
Several analysts recently issued reports on ONVO shares. ValuEngine downgraded Organovo from a “sell” rating to a “strong sell” rating in a report on Friday, September 1st. Zacks Investment Research raised Organovo from a “hold” rating to a “buy” rating and set a $2.25 price target on the stock in a report on Wednesday, October 11th. Jefferies Group reissued a “buy” rating and issued a $4.00 price target on shares of Organovo in a report on Tuesday, September 26th. Raymond James Financial downgraded Organovo from an “outperform” rating to a “market perform” rating and set a $5.00 price target on the stock. in a report on Friday, November 10th. Finally, BTIG Research reissued a “buy” rating and issued a $3.00 price target on shares of Organovo in a report on Thursday, November 16th. Two equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and four have assigned a buy rating to the company. The company presently has a consensus rating of “Hold” and an average target price of $3.60.
Shares of Organovo (NASDAQ ONVO) traded up $0.14 during trading on Monday, reaching $1.65. The company’s stock had a trading volume of 2,448,300 shares, compared to its average volume of 1,079,861. Organovo has a 52-week low of $1.32 and a 52-week high of $4.08.
Organovo (NASDAQ:ONVO) last announced its earnings results on Thursday, November 9th. The medical research company reported ($0.09) earnings per share for the quarter, beating the consensus estimate of ($0.10) by $0.01. The firm had revenue of $1.36 million for the quarter, compared to the consensus estimate of $1.38 million. Organovo had a negative return on equity of 65.63% and a negative net margin of 923.89%. The company’s revenue was down 1.4% compared to the same quarter last year. equities research analysts expect that Organovo will post -0.36 earnings per share for the current fiscal year.
Receive News & Ratings for Organovo Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Organovo Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.